Journey Medical Corporation Expects Topline Results from Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Rosacea

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company, announced that it anticipates releasing topline results from two Phase 3 clinical trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea. The results are e..